Marburg Virus Disease Clinical Trial
Official title:
A Phase 1 Randomized, Single-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP [Angola] (PHV01, MARV GP Vaccine) in Healthy Adults
This is a Phase 1 randomized, single-blind, placebo-controlled, ascending dose study to evaluate the safety and immunogenicity of rVSV∆G-MARV-GP [Angola] (PHV01, Marburg Virus glycoprotein [MARV GP] Vaccine) in healthy adults. PHV01 is a live, attenuated rVSV vaccine expressing the MARV GP. The main questions it aims to answer are: - Which dose of PHV01 is safe to administer to, and well-tolerated by healthy adult subjects? - What is the immunologic response (Marburg-specific Immunoglobulin G (IgG) ELISA antibody and neutralizing antibodies) to each dose level? Participants will receive 1 intramuscular injection of PHV01 or placebo on Day 1 and will be followed for 181 days.
Participants will be randomly assigned to vaccine or placebo in four dose cohorts, starting with evaluation of safety using a sentinel group at each dose level, followed by dosing of the rest of the group in the next cohort. That next cohort will also dose the sentinel group with the next higher dose. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03475056 -
cAd3-Marburg Vaccine in Healthy Adults
|
Phase 1 | |
| Active, not recruiting |
NCT05817422 -
Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults
|
Phase 2 | |
| Completed |
NCT04723602 -
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00605514 -
Ebola and Marburg Virus Vaccines
|
Phase 1 | |
| Completed |
NCT00997607 -
Evaluating an Ebola and a Marburg Vaccine in Uganda
|
Phase 1 | |
| Completed |
NCT03800173 -
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
|
Phase 1 |